Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer?

Iranian Biomedical Journal

Volumn 19, Issue 2, 2015, Pages 69-75

  Khodapasand, Ehsan ^a,b   Jafarzadeh, Narges ^a   Farrokhi, Farid ^a   Kamalidehghan, Behnam ^c   Houshmand, Massoud ^a,b  

^a RAZAVI HOSPITAL   (Iran)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Bax expression; Bax Bcl 2 ratio; Bcl 2 expression; Colorectal cancer

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RNA; BAX PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COLON; COLORECTAL CANCER; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM; RNA EXTRACTION; SIGMOID; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; YOUNG ADULT; AGE; APOPTOSIS; BIOSYNTHESIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOMARKERS, TUMOR; COLON, SIGMOID; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECTUM; RNA, MESSENGER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924674474     PISSN: 1028852X     EISSN: None     Source Type: Journal    
DOI: 10.6091/ibj.1366.2015     Document Type: Article

References (28)

1. Haggar FA, Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009 Nov; 22(4):191-7.
2. Ward S, Hepburn E, Li K, Curbishley S, Hejmadi R, Ismail T, Bicknell R, Rot A, Adams D: Selective recruitment and retainment of regulatory T cells in human colorectal cancer. The Lancet. 2013; 381:S113.
3. Sun N, Meng Q, Tian A: Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. Am J Surg. 2010 Sep; 200(3):341-5.
4. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011 Mar 4; 144(5):646-74.
5. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000 Jan 7; 100(1):57-70.
6. Yip KW, Reed JC: Bcl-2 family proteins and cancer. Oncogene. 2008 Oct 27; 27(50):6398-406.
7. Mohan S, Abdelwahab SI, Kamalidehghan B, Syam S, May KS, Harmal NSM, Shafifiyaz N, Hadi AHA, Hashim NM, Rahmani M: Involvement of NF-κB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A. Phytomedicine. 2012; 19(11):1007-15.
8. Hector S, Prehn JH: Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta. 2009 Apr; 1795(2):117-29.
9. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3; 290(5493):989-92.
10. Rashmi R, Kumar S, Karunagaran D: Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis. 2005 Apr; 26(4):713-23.
11. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HT et al: Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007 May 7; 96(9):1409-18.
12. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999 May; 17(5):1364-74.
13. Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ, Kuppen PJ: The prognostic Value of the Apoptosis pathway in colorectal Cancer: A Review of the Literature on Biomarkers Identified by Immunohistochemistry. Biomarkers in cancer. 2013; 5:13.
14. Tsamandas AC, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T, Kalofonos H, Vagianos CE, Scopa CD: Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome. In Vivo. 2007 Jan-Feb; 21(1):113-8.
15. Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, Posey J, 3rd, Bumpers HL, Meleth S, Grizzle WE et al: Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010 Dec; 1(2):76-89.
16. Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, et al. Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010 Dec; 1(2):76-89.
17. Packham G: Mutation of BCL-2 Family Proteins in Cancer. Apoptosis. 1998 Mar; 3(2):75-82.
18. Jansson A, Sun XF: Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol. 2002 Feb 1; 20(3):811-6.
19. Zhao DP, Ding XW, Peng JP, Zheng YX, Zhang SZ: Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B. 2005 Dec; 6(12):1163-9.
20. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y, Pyrhonen S: Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology. 2003; 64(4):435-42.
21. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC: The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol. 2001 Aug; 117(2):333-40.
22. Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J, Bermejo JL: Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer. 2010; 10:688.
23. Bufill JA: Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location. Annals of Internal Medicine. 1990; 113(10):779-88.
24. Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA: Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009 Aug; 52(8):1359-66.
25. Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, Dellapasqua S, Daidone MG, Costa A: Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer. 2001 Mar 2; 84(5):651-8.
26. Paul-Samojedny M, Kokocinska D, Samojedny A, Mazurek U, Partyka R, Lorenz Z, Wilczok T: Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. Biochim Biophys Acta. 2005 Jun 30; 1741(1-2):25-9.
27. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G, Wei D: Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 2011 Dec; 113(8):810-4.
28. De Angelis PM, Stokke T, Thorstensen L, Lothe RA, Clausen OP: Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. Mol Pathol. 1998 Oct; 51(5):254-61.